Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.48 Insider Own3.72% Shs Outstand4.06M Perf Week-7.19%
Market Cap5.24M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.91M Perf Month-51.69%
Income-13.98M PEG- EPS next Q- Inst Own9.04% Short Float0.65% Perf Quarter-60.67%
Sales1.78M P/S2.94 EPS this Y- Inst Trans-16.15% Short Ratio0.89 Perf Half Y-61.38%
Book/sh2.04 P/B0.63 EPS next Y- ROA-69.66% Short Interest0.03M Perf Year-65.53%
Cash/sh2.15 P/C0.60 EPS next 5Y- ROE-93.11% 52W Range1.12 - 7.12 Perf YTD-60.79%
Dividend Est.- P/FCF- EPS past 5Y53.33% ROI-133.68% 52W High-81.88% Beta1.43
Dividend TTM- Quick Ratio2.43 Sales past 5Y5.27% Gross Margin22.81% 52W Low15.18% ATR (14)0.21
Dividend Ex-Date- Current Ratio2.55 EPS Y/Y TTM50.83% Oper. Margin-782.06% RSI (14)23.48 Volatility16.60% 13.14%
Employees34 Debt/Eq0.35 Sales Y/Y TTM18.24% Profit Margin-785.58% Recom1.00 Target Price100.00
Option/ShortNo / Yes LT Debt/Eq0.26 EPS Q/Q57.45% Payout- Rel Volume2.32 Prev Close1.18
Sales Surprise- EPS Surprise- Sales Q/Q-7.82% EarningsMar 28 AMC Avg Volume28.53K Price1.29
SMA20-31.02% SMA50-49.32% SMA200-62.59% Trades Volume66,267 Change9.32%
Apr-02-24 10:31AM
Mar-28-24 11:52PM
Feb-21-24 04:05PM
Jan-02-24 07:00AM
02:17PM Loading…
Nov-15-23 02:17PM
Nov-14-23 07:00AM
Nov-08-23 08:12AM
Nov-07-23 07:00AM
Aug-10-23 05:15PM
Aug-03-23 08:00AM
Jul-18-23 08:00AM
Jun-27-23 08:00AM
Jun-20-23 08:00AM
May-23-23 08:30AM
05:15PM Loading…
May-15-23 05:15PM
May-08-23 08:00AM
May-02-23 05:10PM
Apr-20-23 05:10PM
Apr-17-23 06:00PM
Apr-04-23 08:30AM
Mar-30-23 08:30AM
Mar-21-23 05:15PM
Mar-17-23 07:00AM
Mar-16-23 05:15PM
Mar-14-23 08:30AM
Mar-09-23 08:30AM
Mar-01-23 07:14AM
Feb-23-23 08:30AM
02:04PM Loading…
Feb-21-23 02:04PM
Feb-03-23 08:31AM
Jan-12-23 08:30AM
Dec-13-22 08:30AM
Dec-05-22 08:30AM
Nov-10-22 05:15PM
Oct-25-22 08:30AM
Oct-21-22 02:39PM
Oct-20-22 08:30AM
Sep-19-22 08:30AM
Sep-16-22 05:05PM
Aug-11-22 05:15PM
Aug-09-22 08:00AM
Jul-26-22 08:30AM
May-18-22 05:15PM
May-16-22 08:55AM
May-12-22 05:15PM
Apr-26-22 08:30AM
Mar-31-22 05:25PM
Mar-24-22 08:30AM
Jan-27-22 07:30AM
Jan-13-22 08:30AM
Dec-27-21 05:10PM
Dec-22-21 12:00PM
Dec-21-21 08:30AM
Dec-07-21 08:30AM
Dec-01-21 08:30AM
Nov-10-21 05:15PM
Nov-08-21 03:00PM
Oct-19-21 08:30AM
Sep-15-21 08:30AM
Aug-18-21 01:45PM
Aug-11-21 05:15PM
Aug-05-21 10:39AM
Aug-03-21 08:30AM
Jun-22-21 08:30AM
Jun-18-21 09:30AM
Jun-14-21 09:30AM
Jun-02-21 08:30AM
May-20-21 08:30AM
May-12-21 05:20PM
Apr-27-21 08:30AM
Apr-21-21 08:17AM
Mar-23-21 08:30AM
Mar-15-21 05:15PM
Mar-08-21 08:30AM
Feb-24-21 08:30AM
Feb-23-21 05:30PM
Feb-18-21 09:00AM
Feb-17-21 08:30AM
Feb-16-21 05:00PM
Feb-11-21 12:30AM
Feb-08-21 08:30AM
Feb-02-21 12:00PM
Jan-28-21 08:30AM
Jan-26-21 09:00PM
Jan-22-21 08:00AM
Jan-21-21 05:25PM
Jan-19-21 08:00AM
Jan-14-21 08:30AM
Jan-12-21 05:15PM
Jan-08-21 09:00AM
Jan-06-21 08:30AM
Jan-05-21 08:30AM
Dec-29-20 05:15PM
Dec-09-20 08:30AM
Dec-02-20 08:00AM
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nuzum Charles Lee SrDirectorSep 25 '23Sale3.0410,00030,38724,033Sep 27 05:03 PM